BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 16200237)

  • 1. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 3. [Bile acids in liver diseases--current indications].
    Stiehl A
    Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
    Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
    J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
    Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
    Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cholestasis: therapeutic options].
    Beuers U; Oswald M
    Ther Umsch; 1998 Feb; 55(2):97-103. PubMed ID: 9545851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
    Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
    Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
    Luketic VA; Sanyal AJ
    Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
    Mazzella G; Rizzo N; Azzaroli F; Simoni P; Bovicelli L; Miracolo A; Simonazzi G; Colecchia A; Nigro G; Mwangemi C; Festi D; Roda E
    Hepatology; 2001 Mar; 33(3):504-8. PubMed ID: 11230728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
    Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
    J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy.
    Meng LJ; Reyes H; Axelson M; Palma J; Hernandez I; Ribalta J; Sjövall J
    Hepatology; 1997 Dec; 26(6):1573-9. PubMed ID: 9398000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
    van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
    Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.